Amino acid block modified gadolinium-based contrast agent and application thereof
By replacing the amino acid chunk of the gadolinium magnetic resonance imaging contrast agent, a new gadolinium-based contrast agent with good relaxation rate, low toxicity and stability was designed, and the non-specific distribution of gadolinium-based contrast agent in the prior art was solved and Toxicity problems improve imaging efficiency and stability and have good clinical application prospects.
CN119080875APending Publication Date: 2024-12-06LANZHOU UNIV
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CN202411411501.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-10
- Publication Date
- 2024-12-06
Smart Images

Figure BDA0005078122420000021 
Figure FDA0005078122410000011 
Figure HDA0005078122430000011
Abstract
The invention discloses an amino acid block modified gadolinium-based contrast agent which is prepared by taking XK (epsilon-DOTA-Gd) X as a template and carrying out amino acid block replacement on two X so as to adjust hydrophilicity. The amino acid chunks are preferably glycine (Gly, G), serine (Ser, S), threonine (Thr, T), tyrosine (Tyr, Y), phenylalanine (Phe, F) or alanine (Ala, A). An in-vitro imaging experiment, a hemolytic activity experiment and a plasma stability experiment show that the synthesized amino acid block modified gadolinium-based contrast agent has good relaxation rate, low toxicity and good stability. Therefore, the amino acid blocking gadolinium-based contrast agent can be used for preparing clinical magnetic resonance imaging diagnostic drugs.
Need to check novelty before this filing date? Find Prior Art
